Non-functioning Pancreatic Neuroendocrine Tumors (NF-pNETs) in Multiple Endocrine Neoplasia Type 1 (MEN1) Treated With Somatostatin Analogs (SA) Versus NO Treatment - a Prospective, Randomized, Controlled Multicenter Study
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 21 Apr 2017
At a glance
- Drugs Lanreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms SANO
- 13 Apr 2017 Planned number of patients changed from 100 to 180.
- 13 Apr 2017 Planned End Date changed from 1 Jun 2022 to 1 Jun 2023.
- 13 Apr 2017 Planned primary completion date changed from 1 Jun 2021 to 1 Jun 2022.